FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*						2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) 777 OLD SAW MILL RIVER ROAD					3.	3. Date of Earliest Transaction (Month/Day/Year) 08/20/2020								Officer (give title Oth below) belo				ner (specify ow)	
(Street) TARRY (City)		Y 10591 tate) (Zip)				If Am	endme	ent, Date	of Origina	al File	ed (Month/D		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
		Ta	ble I - No	on-Der	ivativ	ve S	ecur	ities A	cquire	d, Di	sposed	of, or Be	eneficia	lly Owned					
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Ye		Year) Exec		emed on Date, /Day/Year	Transaction Dispo		Disposed	rities Acquired (A) or ed Of (D) (Instr. 3, 4 ar		5. Amount o Securities Beneficially Owned Follo Reported	Form: Di (D) or In		rect Ir lirect B 4) C	ndirec enefic wners	Nature of direct eneficial wnership nstr. 4)		
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)						
Common	Stock													1,150		I		by Spouse	
Common Stock													400		I		by Spouse/Cust Son		
Common Stock											4,700		I		by Trust for Son				
			Table II								posed of			y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed Date,	te, Transacti Code (Ins		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivativ Security (Instr. 3 and 4)			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	ıble	Expiration Date	Title	Amount Number Shares						
Non- Qualified Stock Option (right to buy)	\$57.11	08/20/2020			M			10,000	(1)		01/03/2022	Common Stock	10,000	\$0.0	5,	.000	D		
Non- Qualified Stock Option (right to buy)	\$57.11	08/21/2020			М			5,000	(1)		01/03/2022	Common Stock	5,000	\$0.0		0	D		
Non- Qualified Stock Option (right to buy)	\$177.82	08/21/2020			М			4,963	(1)		01/02/2023	Common Stock	4,963	\$0.0	10	10,037			
Non- Qualified Stock Option (right to	\$177.82	08/24/2020			M			10,037	(1)		01/02/2023	Common Stock	10,037	\$0.0		0	D		

Explanation of Responses:

- $1. \ The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.\\$
- 2. Form two of two

/s/**George L. Sing

08/24/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.